Increased expression of differentiation markers can accompany laminin-induced attachment of small cell lung cancer cells.
We investigated the interaction between human lung cancer cells, laminin, and several differentiating agents. When grown on laminin coated substrate eight out of 11 small cell lung cancer (SCLC) cell lines exhibited attachment to laminin and three had extensive outgrowth of long neurite-like processes. Of seven non-small cell lung cancer cell lines, selected for their in vitro anchorage-independent growth, attachment was observed in only three cell lines, and process formation was far less extensive than in SCLC cell lines. Among several differentiating agents, only dcAMP, which alone induced attachment and some process formation, increased laminin-mediated attachment and process formation of two SCLC cell lines, NCI-N417 a variant cell line, and NCI-H345, a classic cell line. The expression of several neuroendocrine and neuronal markers was investigated in these two SCLC cell lines. The expression of the light subunit of neurofilaments increased in NCI-N417 within 3 to 4 days of seeding, while NCI-H345 exhibited approximately 5 fold increase in expression of the GRP gene and a 3 fold increase expression of the beta-actin gene. The expression of a number of other neuroendocrine and neuronal markers did not change following growth on laminin. The doubling times remained unchanged independent of the presence of and attachment to laminin while topoisomerase II gene expression levels in NCI-N417 cells decreased approximately 5 fold when cells were growing on laminin.
Giaccone
G
G
National Cancer Institute, NCI-Navy Medical Oncology Branch, National Institutes of Health, Bethesda, Maryland.
Broers
J
J
Jensen
S
S
Fridman
R I
RI
Linnoila
R
R
Gazdar
A F
AF
D000081:Acetamides / Q000494:pharmacology; D000199:Actins / Q000378:metabolism; D003994:Bucladesine / Q000494:pharmacology; D018288:Carcinoma, Small Cell / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology*; D002454:Cell Differentiation; D002455:Cell Division; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D019886:Gastrin-Releasing Peptide; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000378:metabolism; D006801:Humans; D007382:Intermediate Filaments / Q000378:metabolism; D007797:Laminin / Q000502:physiology*; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D010455:Peptides / Q000378:metabolism; D013806:Theophylline / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000081:Acetamides; D000199:Actins; D007797:Laminin; D010455:Peptides; D003994:Bucladesine; D019886:Gastrin-Releasing Peptide; D013806:Theophylline; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; C014026:hexamethylene bisacetamide; D004121:Dimethyl Sulfoxide